Gaia Skibinski
Gaia Skibinski
System1
system1.bio üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
G Skibinski, NJ Parkinson, JM Brown, L Chakrabarti, SL Lloyd, ...
Nature genetics 37 (8), 806-808, 2005
8562005
Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦
K Nakamura, VM Nemani, F Azarbal, G Skibinski, JM Levy, K Egami, ...
Journal of Biological Chemistry 286 (23), 20710-20726, 2011
5452011
ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)
N Parkinson, PG Ince, MO Smith, R Highley, G Skibinski, PM Andersen, ...
Neurology 67 (6), 1074-1077, 2006
4522006
Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis
SJ Barmada, G Skibinski, E Korb, EJ Rao, JY Wu, S Finkbeiner
Journal of Neuroscience 30 (2), 639-649, 2010
4502010
In silico labeling: predicting fluorescent labels in unlabeled images
EM Christiansen, SJ Yang, DM Ando, A Javaherian, G Skibinski, S Lipnick, ...
Cell 173 (3), 792-803. e19, 2018
3092018
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies
G Skibinski, K Nakamura, MR Cookson, S Finkbeiner
Journal of Neuroscience 34 (2), 418-433, 2014
1372014
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson’s disease
G Toth, SJ Gardai, W Zago, CW Bertoncini, N Cremades, SL Roy, ...
PloS one 9 (2), e87133, 2014
1182014
Nrf2 mitigates LRRK2-and α-synuclein–induced neurodegeneration by modulating proteostasis
G Skibinski, V Hwang, DM Ando, A Daub, AK Lee, A Ravisankar, ...
Proceedings of the National Academy of Sciences 114 (5), 1165-1170, 2017
772017
iPS cells in the study of PD molecular pathogenesis
MM Cobb, A Ravisankar, G Skibinski, S Finkbeiner
Cell and tissue research 373 (1), 61-77, 2018
232018
Drug discovery in Parkinson’s disease—Update and developments in the use of cellular models
G Skibinski, S Finkbeiner
International journal of high throughput screening 2011 (2), 15, 2011
232011
Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease
G Skibinski, S Finkbeiner
FEBS letters 587 (8), 1139-1146, 2013
192013
Frontotemporal dementia linked to chromosome 3
J Brown, S Gydesen, P Johannsen, A Gade, G Skibinski, L Chakrabarti, ...
Dementia and geriatric cognitive disorders 17 (4), 274-276, 2004
122004
A three‐groups model for high‐throughput survival screens
BA Shaby, G Skibinski, M Ando, ES LaDow, S Finkbeiner
Biometrics 72 (3), 936-944, 2016
52016
Optimization and scaling of patient-derived brain organoids uncovers deep phenotypes of disease
K Shah, R Bedi, A Rogozhnikov, P Ramkumar, Z Tong, B Rash, M Stanton, ...
bioRxiv, 2020
32020
Preclinical signs of impairment in persons at high risk of frontotemporal dementia related to chromosome 3 (FTD3): Preliminary findings in neuropsychological tests
A Gade, G Skibinski, S Gydesen
Neurobiol Aging 25 (suppl 2), S453, 2004
22004
The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity
AED Stormo, M FitzGibbon, F Shavarebi, EM Earley, LS Lum, ...
BioRxiv, 2020
12020
Mutations in the endosomal ESCRTIII complex subunit CHMP2B in frontotemporal dementia
G Skibinski, N Parkinson, E Fisher, J Collinge, Freja Consortium
CAMBRIDGE UNIV PRESS 88 (1), 75-76, 2006
12006
Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinson’s patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006)
G Novak, S Finkbeiner, G Skibinski, A Skupin
Stem Cell Research, 102569, 2021
2021
Computational Cell-Barcoding for High-Throughput Robotic Microscopy
M Barch, G Skibinski, A Lee, S Finkbeiner
Biophysical Journal 112 (3), 303a-304a, 2017
2017
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
S Finkbeiner, G Tóth, SJ Gardai, W Zago, CW Bertoncini, N Cremades, ...
2014
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20